Pharma Focus Asia

Merck Invests US$31 million (€29 million) to Complete Biologics Testing Centre in Shanghai, China


Merck with an investment of US$31 million (€29 million) has completed the construction of  new biologics testing centre in Shanghai, China.


The testing centre not only provides cGMP-compliant lot release testing for unprocessed and purified bulk harvests but also ensures that these tests meet the stringent requirements for biologics entering preclinical and clinical studies, as well as licenced biologics.

Expanding on the existing lab space established just last year, the centre plans to increase its area by 1,500 square metres. This expansion will occur in two phases:

The initial phase focuses on augmenting testing services specifically tailored for viral clearance studies.

In the second phase, the centre will enhance its capabilities to conduct thorough cell line characterisations. These added capabilities are designed to support biopharmaceutical customers by meticulously assessing and verifying the safety, purity, and identity of their cell banks.

These new biosafety labs provide unprecedented access to diverse testing services for cell line characterisation and lot release, spanning from pre-clinical development to  commercialisation.

The facility's phase two completion has expanded its scope to encompass a wide array of biosafety testing services. It now caters to monoclonal antibodies, various recombinant proteins, as well as cell and gene therapies.


Name    Merck
Type      New Construction
Budget   US$31 million (€29 million)

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference